One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Global CDK 4/6 Inhibitor Drugs Market

世界のCDK4 / 6阻害薬市場市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Global CDK 4/6 Inhibitor Drugs Market Outlook 2030


Product Code : Research NesterHC00116099
Survey : Research Nester
Publish On : November, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Pfizer Inc., Novartis AG, Eli Lilly and Company

[Report Description]

Global CDK 4/6 Inhibitor Drugs Market Analysis 2020-2030

CDK 4/6 inhibitor is a class of drugs that target enzymes called CDK4 and CDK6. They are designed to interrupt the growth of cancer cells. CDK 4/6 inhibitor drugs currently used to treat metastatic breast cancer are abemaciclib, palbociclib, and ribociclib. The global CDK 4/6 inhibitor drugs market is anticipated to grow with a CAGR of 13.2% over the forecast period, i.e., 2021 – 2030. Factors such as the increasing concern for the rising prevalence of breast cancer around the globe, and the need to treat the disease at an early stage are anticipated to contribute to the market growth. Moreover, factors such as the rising research and developments in the field of cancer drugs, and the surge in research expenditure, are also expected to boost the market growth. The global CDK 4/6 inhibitor drugs market is estimated to garner a revenue of close to USD 42510 Million by the end of 2030, up from a revenue of about USD 6990 Million in the year 2020.
The global CDK 4/6 inhibitor drugs market is segmented by numerous segments, which include segmentation by drug type into palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Amongst all these segments, the palbociclib (Ibrance) segment is expected to generate the largest revenue of over USD 37650 Million by the end of 2030. Further, the market generated a revenue of near to USD 5390 Million in the year 2020.
The global CDK 4/6 inhibitor drugs market is segmented by region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these, the market in North America region is anticipated to garner the largest revenue of around USD 30200 Million by the end of 2030. Additionally, in the year 2020, the market in the region attained a revenue of near to USD 4990 Million.
Some of the prominent industry leaders in the global CDK 4/6 inhibitor drugs market that are included in our report are Pfizer Inc., Novartis AG, Eli Lilly and Company, and others.

Global CDK 4/6 Inhibitor Drugs Market TOC

1. Market Definition and Research Methodology
1.1. Market Definition and Segmentation
1.2. Assumptions and Acronyms
1.3. Research Objective
1.4. Research Methodology
2. Executive Summary
3. Industry Value Chain Analysis
4. Market Dynamics
4.1. Drivers
4.2. Challenges
4.3. Trends
4.4. Opportunities
5. Regulatory & Standards Landscape
6. Industry Risk Analysis
7. Industry Growth Outlook
8. Growth Opportunity Analysis for Business Development
9. Impact of COVID-19 on the Global CDK 4/6 Inhibitor Drugs Market
10. Average Pricing Analysis
11. Comparative Analysis
12. Competitive Landscape
13. Product Pipeline Analysis
14. Global CDK 4/6 Inhibitor Drugs Market
14.1. By Value (USD Million)
14.2. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis 2020-2030
14.2.1. By Drug Type
14.2.1.1. Palbocilib (Ibrance)
14.2.1.2. Ribocilib (Kisqali)
14.2.1.3. Abemaciclib (Verzenio)
14.2.2. By Patient
14.2.2.1. Pre-Menopausal
14.2.2.2. Post-Menopausal
14.2.2.3. Others
14.2.3. By End-Users
14.2.3.1. Hospitals
14.2.3.2. Clinics
14.2.3.3. Research Laboratories
14.2.3.4. Retail Pharmacies
14.2.4. By Region
14.2.4.1. North America
14.2.4.2. Europe
14.2.4.3. Asia Pacific
14.2.4.4. Latin America
14.2.4.5. Middle East & Africa
15. North America CDK 4/6 Inhibitor Drugs Market
15.1. Market by Value (USD Million)
15.1.1. By Drug Type
15.1.1.1. Palbocilib (Ibrance)
15.1.1.2. Ribocilib (Kisqali)
15.1.1.3. Abemaciclib (Verzenio)
15.1.2. By Patient
15.1.2.1. Pre-Menopausal
15.1.2.2. Post-Menopausal
15.1.2.3. Others
15.1.3. By End-Users
15.1.3.1. Hospitals
15.1.3.2. Clinics
15.1.3.3. Research Laboratories
15.1.3.4. Retail Pharmacies
15.1.4. By Country
15.1.4.1. United States
15.1.4.2. Canada
16. Europe CDK 4/6 Inhibitor Drugs Market
16.1. Market by Value (USD Million)
16.1.1. By Drug Type
16.1.2. By Patient
16.1.3. By End-Users
16.1.4. By Country
16.1.4.1. United Kingdom
16.1.4.2. Germany
16.1.4.3. France
16.1.4.4. Italy
16.1.4.5. Spain
16.1.4.6. Russia
16.1.4.7. Netherlands
16.1.4.8. Rest of Europe
17. Asia Pacific CDK 4/6 Inhibitor Drugs Market
17.1. Market by Value (USD Million)
17.1.1. By Drug Type
17.1.2. By Patient
17.1.3. By End-Users
17.1.4. By Country
17.1.4.1. China
17.1.4.2. India
17.1.4.3. Japan
17.1.4.4. South Korea
17.1.4.5. Singapore
17.1.4.6. Australia
17.1.4.7. Rest of Asia Pacific
18. Latin America CDK 4/6 Inhibitor Drugs Market
18.1. Market by Value (USD Million)
18.1.1. By Drug Type
18.1.2. By Patient
18.1.3. By End-Users
18.1.4. By Country
18.1.4.1. Brazil
18.1.4.2. Mexico
18.1.4.3. Argentina
18.1.4.4. Rest of Latin America
19. Middle East & Africa CDK 4/6 Inhibitor Drugs Market
19.1. Market by Value (USD Million)
19.1.1. By Drug Type
19.1.2. By Patient
19.1.3. By End-Users
19.1.4. By Country
19.1.4.1. GCC
19.1.4.2. Israel
19.1.4.3. South Africa
19.1.4.4. Rest of Middle East & Africa

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+